The terms Laetrile, Amygdalin, and Vitamin B17 are often used interchangeably, leading to confusion regarding their nature and therapeutic potential, particularly in the realm of cancer treatment. This article from NINGBO INNO PHARMCHEM CO.,LTD. aims to clarify these distinctions and present the scientific perspective on these compounds.

Amygdalin is a naturally occurring cyanogenic glycoside found in the seeds of various fruits, most notably apricot kernels. It is a complex molecule that, when metabolized, can release cyanide. Laetrile, on the other hand, is a semi-synthetic derivative of amygdalin that was developed with the intention of being used as a cancer treatment. It is important to note that neither amygdalin nor Laetrile is recognized as a vitamin (like Vitamin B17), despite claims to the contrary. The designation of 'Vitamin B17' is a marketing term and lacks scientific validation.

The purported anti-cancer mechanism of Laetrile and amygdalin revolves around the idea that cyanide, released from these compounds, selectively destroys cancer cells. The theory suggests that cancer cells possess an enzyme that activates cyanide, while healthy cells are able to neutralize it. However, extensive scientific research has failed to substantiate this selective toxicity. Numerous studies, including clinical trials, have not found reliable evidence that amygdalin or Laetrile can effectively treat or prevent cancer. Instead, significant concerns have been raised about the potential for cyanide poisoning, a severe adverse effect that can arise from the consumption of these substances, especially when taken orally.

The lack of scientific evidence for efficacy, combined with the significant safety risks, has led regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to ban the sale of Laetrile. This ban highlights the prevailing scientific consensus: that amygdalin and its derivatives are not proven cancer treatments and pose serious health risks. While NINGBO INNO PHARMCHEM CO.,LTD. acknowledges the ongoing scientific exploration of natural compounds, we emphasize the importance of evidence-based medicine. The promotion of amygdalin or Laetrile as a vitamin b17 cancer cure is considered misinformation and potentially harmful. Relying on such unproven methods can delay or replace conventional cancer treatments that have established efficacy and safety profiles. Understanding the distinction between these terms and the scientific reality behind them is crucial for informed health decisions regarding amygdalin cancer treatment and laetrile cancer therapy.